Impact of hypogonadism on bone mineral density and vertebral fractures in HIV-infected men

L. C. Pezzaioli · T. Porcelli · A. Delbarba · F. Maffezzoni · E. Focà · F. Castelli · C. Cappelli · A. Ferlin · M. E. Quiros-Roldan

Received: 1 June 2021 / Accepted: 20 August 2021 / Published online: 30 August 2021
© The Author(s) 2021

Abstract
Purpose Hypogonadism and osteoporosis are frequently reported in HIV-infected men and, besides multifactorial pathogenesis, they might be directly linked because of testicular involvement in bone health. We evaluated the prevalence of osteoporosis and vertebral fractures (VFs) in HIV-infected men, and assessed their relationship with gonadal function.

Methods We enrolled 168 HIV-infected men (median age 53). Osteoporosis and osteopenia were defined with T-score ≤ −2.5SD and T-score between −1 and −2.5SD, respectively. VFs were assessed by quantitative morphometric analysis. Total testosterone (TT), calculated free testosterone (cFT), Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) were obtained; overt hypogonadism was defined on symptoms and low TT or cFT, and classified into primary and secondary according to gonadotropins; compensated hypogonadism was defined as normal TT and cFT with high LH levels.

Results Overall, osteoporosis and osteopenia were found in 87.5% of patients, and VFs were detected in 25% of them; hypogonadism was identified in 26.2% of cases. Osteoporotic patients had higher SHBG vs those with normal bone mineral density (BMD). Fractured patients were more frequently hypogonadal and with higher SHBG. SHBG showed negative correlation with both spine and femoral BMD, and positive correlation with VFs. In multivariate models, FSH showed negative impact only on femoral BMD, whereas older age and higher SHBG predicted VFs.

Conclusion We found a high burden of bone disease and hypogonadism in HIV-infected men, and we showed that the impact of gonadal function on bone health is more evident on VFs than on BMD.

Keywords HIV · Vertebral fractures · Osteoporosis · Hypogonadism · SHBG · FSH

Introduction
The introduction of combined antiretroviral therapy (cART) has radically changed the course of HIV infection with an increase in life expectancy, and has therefore, led to an increased prevalence of aging-related diseases, such as hypogonadism and osteoporosis [1]. In addition, HIV infection itself is associated with chronic inflammation and premature aging [2], and HIV + patients experience more aging-associated comorbidities and at an earlier age compared to non-infected counterparts [3].

Hypogonadism results from failure of the testis to produce physiological amounts of testosterone and/or spermatzoa and might depend on alteration at one or more levels of the hypothalamic-pituitary–testicular (HPT) axis [4]. The diagnosis of hypogonadism relies on the combination of low morning testosterone levels and clinical manifestations.
of androgen deficiency [4, 5], including sexual symptoms (reduced libido, erectile dysfunction, decreased spontaneous erections) and less specific signs and symptoms (loss of body/facial hair, decreased testicular volume, increased body fat/reduced muscle mass, central obesity, osteoporosis, asthenia, decreased concentration, etc.) [4]. However, the diagnosis of hypogonadism in men with HIV can be challenging, as they often present with non-specific symptoms or with signs/symptoms overlapping with other comorbidities (e.g., obesity, HCV, diabetes) [1]. Furthermore, sexual symptoms in men with HIV might have multiple causes other than hypogonadism [1].

Osteoporosis is also frequent in HIV-infected subjects [1], who have lower spine and hip bone mineral density (BMD), with a three-fold risk of osteoporosis vs controls [6]. Although data on vertebral fractures (VFs) are less conclusive, previous metanalyses showed a two-folds increased risk of VFs compared to non-infected patients [7, 8]. Importantly, whether low BMD leads to more fractures in HIV-infected patients is still debated [7]. Both hypogonadism and osteoporosis in HIV-infected men have a multifactorial pathogenesis [1, 9], including smoking, alcohol use, physical inactivity, cART effect and chronic immune activation by HIV infection itself [10]. Furthermore, hypogonadism and osteoporosis might be directly associated [1], since testicular function is involved in bone health [11]. In fact, Leydig cells play a role in bone health by producing not only testosterone, but also insulin-like 3 peptide (INSL3), and by contributing to the 25-hydroxylation of vitamin D [12], which may be all involved in BMD maintenance [13]. Reduced testicular function is a known cause of male osteoporosis at all ages also in general population [14]. However, data on the association between testosterone and BMD in HIV-infected males are not conclusive, and data on hypogonadism and VFs in these patients are very scarce. Furthermore, methodologic discrepancies in the assessment of hypogonadism exist among previous studies, and no study with fractures as primary endpoint has been performed [1].

We, therefore, aimed to investigate the prevalence of osteoporosis and VFs in a cohort of HIV-infected men under cART, and to assess their relationship with properly investigated gonadal function.

Methods

Patients and methods

A cross-sectional retrospective study on 168 HIV-infected males was performed. Inclusion criteria were: age > 18 years, serologically documented HIV infection in stable condition under cART, no personal history of malabsorption or drugs with potential detrimental effect on bone, blood samples carried out at central hospital laboratory, DXA scan and quantitative morphometric assay performed with the same densitometer (Explorer Hologic Inc., QDR-4500 W Waltham, MA) according to normative Italian data [15].

DXA results were expressed as BMD (g/cm²) and were collected for both spine, total hip and femoral neck. For patients older than 50 years, T score (standard deviations -SD above or below sex and ethnicity matched population at peak of bone mass) was calculated. According to guidelines, for patients younger than 50 years, both T and Z scores were collected, being Z score SD above or below sex and ethnicity matched population of the same age. However, taking into account the very small number of patients younger than 50 years, and to allow comparison between densitometric parameters, we included only T score for statistical analysis. A T score less than or equal to –2.5 SD in at least one site (spine or hip) was defined as osteoporosis, whereas T score values between –1 and –2.5 SD at both spine and hip sites were diagnostic for osteopenia [16].

VFs were assessed through a quantitative morphometric assay performed on images obtained from DXA by the same operator and by measuring anterior, middle and posterior vertebral heights and height ratios for each vertebra from T5 to L4 [17].

Hypogonadism was defined based on the concurrent presence of suggestive signs/symptoms (reduced libido, morning erections, erectile function) and biochemical findings of low total testosterone (TT) and/or calculated free testosterone (cFT) levels, and subsequently classified according to luteinizing hormone (LH) levels into primary (high LH) and secondary (low/normal LH). cFT was calculated with Vermeulen equation (http://www.issam.ch/freetesto.htm), that combine TT, sex hormone-binding globulin (SHBG) and albumin. Cut-off value for lower limit of TT and cFT were 3.46 ng/ml and ≤ 65 pg/ml, respectively [4, 5]. Normal range for LH was established between 1.5 and 9.4 mUI/ml [4, 5]. Elevated LH with normal TT and cFT levels identified compensated hypogonadism. More details on hypogonadism assessment in this population are shown elsewhere [18].

All blood samples were obtained between 8.00 and 10.00 a.m., after a 12-h overnight fast. Blood and urinary samples were collected for the following biochemical assays: HBV (chemiluminescence microparticle immunoassay—CMIA) and HCV (chemiluminescence immunoassay—CLIA) serostatus, CD4 count (flow cytometry), TT (CMIA), SHBG (CLIA), follicle stimulating hormone (FSH) (CMIA), LH (CMIA), serum and urinary calcium and phosphate, parathyroid hormone (PTH) (CLIA), 25-OH-vitamin D (High-Pressure Liquid Chromatography with UV Detector – HPLC–UV), bone-alkaline phosphatase (affinity electrophoresis), C-terminal telopeptide (Enzyme-linked immunosorbent assay—ELISA), osteocalcin (CLIA). Intra-
inter-assay coefficient of variance for TT, LH and SHBG was < 5%.

Information on smoking and drinking habits were collected. Patients were defined as current smokers if actively smoking at least 1 cigarette/day, and past smokers if they had quit smoking for at least one year. We considered patients as usual drinkers if they drink alcohol at least once a day, and occasional drinkers if they drink once a week or less.

Ethical approval for this study was obtained from Local Ethical Committee (Comitato Etico di Brescia, NP 3898) and informed consent was obtained from all participants.

Statistical analysis

Statistical Package for the Social Sciences software IBM SPSS Statistics, Version 25.0, Armonk, (NY) was used for statistical analysis. Since the variables were not normally distributed (Kolmogorov–Smirnov test was used), comparison between medians of the quantitative variables was performed with non-parametric Kruskal–Wallis H test (followed by post hoc Bonferroni test when a significant difference was found) or Mann–Whitney U test, as appropriate. Comparison between categorial variables was performed with Pearson’s Chi Square. Correlation between bone parameters and clinical and biochemical data was performed with Spearman or point-biserial correlation, as appropriate. To investigate factors associated with BMD, multivariate models were designed, using hierarchical multiple regression analysis. To assess predictive factors for VFs, a backward stepwise logistic regression analysis was performed. All multiple regression analyses were preceded by univariate analyses to identify candidate predictive variables. Receiver operating characteristic (ROC) curves were used to study sensitivity and specificity of FSH, testosterone and SHBG in identifying patients with normal BMD from those with osteopenia/osteoporosis and with and without VFs. Area under the curve (AUC) < 0.5 would not discriminate affected and non-affected patients. P values < 0.05 were considered statistically significant.

Results

Characteristics of the study participants, according to bone mineral status and to VFs, are shown in Table 1. Median age of the whole population was 53 years (IQR 49–57). Only 21/168 patients (12.5%) had normal BMD, whereas 89/168 (53.0%) had osteopenia, and 58/168 (34.5%) had osteoporosis. In 42/168 (25.0%) of the patients, at least one VF was detected. Of them, 22/42 (52.4%) were osteoporotic, 19/42 (45.2%) had osteopenia, and one of them (2.4%) had normal BMD. Regarding gonadal function, 44/168 (26.2%) patients were diagnosed with hypogonadism, including overt (low TT or cFT) and compensated forms (normal testosterone with high LH). Of them, 21/44 (47.8%) had overt hypogonadism: 5/21 (23.8%) had primary and 16/21 (76.2%) had secondary/normogonadotropic hypogonadism. Besides antiretroviral therapy, 9/168 patients (5.4%) were taking calcium supplementation, and 91/168 (54.2%) were already taking adequate vitamin D supplementation.

Osteoporotic patients had BMI values significantly lower than patients with osteopenia or normal BMD (p = 0.001). Furthermore, osteoporotic patients, compared to those with normal BMD or osteopenia, were more frequently active smokers (p = 0.027) and drug users (p = 0.004), had longer HIV infection duration (p = 0.035), were more frequently HCV coinfected (p = 0.015), and showed a higher burden of VFs (p = 0.006). Finally, osteoporotic patients had higher SHBG values compared to those with normal BMD (p = 0.034).

The comparison of patients with and without VFs showed that fractured patients were older (median age 55 vs 52 years, p = 0.048), more frequently drug users (p = 0.047), had longer HIV infection duration and cART exposure (p = 0.015 and p = 0.002, respectively), and were more frequently hypogonadal (p = 0.044) and with higher SHBG values (p = 0.010). BMD data were worse in men with VFs with respect to men without VFs.

The relationship between bone mineral status (including BMD, T-score and VFs) and main clinical, virological and biochemical data is shown in Table 2 (and Fig. 1 for gonadal function insight). With respect to BMD data, the strongest positive correlations were between BMI and both spine and femoral BMD and T scores. HIV infection duration was negatively associated with femoral BMD and T scores and with spine T score, and a significant positive correlation was found between total hip BMD and CD4+ count. Focusing on gonadal function, TT levels had moderate-to-strong negative correlation with total hip BMD and with total hip and femoral neck T scores. FSH and LH values showed strong negative correlation with total hip T score, and FSH showed further negative correlation with total hip BMD and femoral neck T score. SHBG levels showed negative correlation with spine BMD, and spine, total hip and femoral neck T scores. With respect to VFs, age, HIV infection and cART duration were positively associated with their presence. Among hormonal data, only SHBG was positively associated with VFs.

Then, the association between BMD and clinical, virological and biochemical parameters was investigated through univariate and multivariate models. For spine BMD model, no correlation was found at multivariate analysis. In Table 3, the results of hierarchical multiple regression analysis for total hip BMD are shown. We entered variables in four different steps, with each independent variable being assessed for what it might add to the prediction of total hip BMD variance, after the previous variables were controlled for. Once
Table 1  Comparison between patients with normal BMD, osteopenia and osteoporosis, and between patients with vertebral fractures vs patients without vertebral fractures

| Total (n. 168) | Normal values (n. 21) | Normal BMD (n. 89) | Osteopenia (n. 58) | Osteoporosis (n. 58) | P value | No vertebral fractures (n. 126) | Vertebral fractures (n. 42) | P value |
|----------------|-----------------------|--------------------|-------------------|---------------------|---------|---------------------------------|---------------------------|---------|
| Age (years)    | 53 (46–60)            | 54 (49–57)         | 52 (49–57)        | 0.840               | 52 (48–57) | 55 (51–60)                     | 24.6 (21.1–27.1)          | 0.048   |
| BMI (kg/m²)    | 25.2 (22.7–28.7)*     | 25.7 (23–27.9)*    | 22.7 (20.8–25.9)**| 0.001               | 25.0 (22.3–27.2) |                                  |                           | 0.477   |
| Smoke          |                       |                    |                   |                     |         |                                |                           |         |
| Current smoker, # (%) | 6/18 (33.3) | 29/72 (40.3) | 30/44 (68.2) | 0.027               | 45/100 (45) | 20/34 (58.8)                 |                            | 0.271   |
| Past smoker, # (%) | 3/18 (16.7)  | 11/72 (15.3)   | 2/44 (4.5)        | 14/100 (14)         | 2/34 (5.9)   |                                |                           |         |
| Alcohol        |                       |                    |                   |                     |         |                                |                           |         |
| Usual drinker, # (%) | 3/18 (16.7) | 21/68 (30.9) | 12/44 (27.3) | 0.715               | 25/95 (26.3) | 11/35 (31.4)                 |                            | 0.785   |
| Occasional drinker, # (%) | 10/18 (55.6) | 30/68 (44.1) | 18/44 (40.9) | 44/95 (46.3) | 14/35 (40)   |                                |                           |         |
| Drug user, # (%) | 5/20 (25)           | 20/77 (26)        | 27/51 (52.9)     | 0.004               | 34/111 (30.6) | 18/37 (48.6)                 |                            | 0.047   |
| HIV infection duration (years) | 11 (6–20.5)*  | 11.5 (6–20)*      | 17 (10.5–24.5)** | 0.035               | 11 (8–20) | 18 (9–25)                     |                            | 0.015   |
| cART duration (years) | 11 (5–16.5)  | 8.5 (5–16.8)      | 13 (8.8–18)      | 0.087               | 10 (7–16) | 14 (7.5–18)                   |                            | 0.002   |
| CD4 + nadir (cell/mm³) | 190 (62–325.5) | 173 (55.5–287.5) | 120 (52–248) | 0.523               | 150 (59–292) | 127.5 (48.5–223) |                           | 0.300   |
| CD4 + at inclusion (cell/mm³) | 18.9 (11.6–22.9) | 14.9 (8.7–22.1) | 14 (7.7–22.6) | 0.533               | 14.9 (8.3–22.2) | 15.2 (9.7–22.1) |                           | 0.987   |
| CD4 + at inclusion (%) | 310–580 | 32.8 (24.9–38) | 31.8 (25.5–37.9) | 29.6 (21.7–34.9) | 0.326 | 31.5 (23.9–37.8) | 32.1 (25.2–35.7) | 0.799   |
| AIDS, # (%)    | 5/21 (23.8)          | 24/81 (29.6)      | 16/52 (30.8)     | 0.834               | 31/116 (26.7) | 14/38 (36.8)                 |                            | 0.234   |
| HBsAg +, # (%) | 1/21 (4.8)           | 5/79 (6.3)        | 5/54 (9.3)       | 0.732               | 8/116 (6.9) | 3/38 (7.9)                    |                            | 0.836   |
| HCV Ab +, # (%) | 7/21 (33.3)          | 27/81 (33.3)      | 30/52 (57.7)     | 0.015               | 44/116 (37.9) | 20/38 (52.6)                 |                            | 0.111   |
| Diabetic, # (%) | 3/21 (14.3)          | 12/89 (13.5)      | 8/58 (13.8)      | 0.995               | 16/126 (12.7) | 7/42 (16.7)                   |                            | 0.515   |
| Chronic kidney disease, # (%) | 1/21 (4.8)  | 6/89 (6.7)        | 4/58 (6.9)       | 0.939               | 7/126 (5.6) | 4/42 (9.5)                    |                            | 0.368   |
| Hypogonadism, # (%) | 4/19 (21.1)  | 22/83 (26.5)      | 18/53 (34)       | 0.482               | 29/119 (24.4) | 15/36 (41.2)                 |                            | 0.044   |
| Type of hypogonadism |           |                    |                   |                     |         |                                |                           |         |
| Primary, # (%) | 1/4 (25)             | 2/21 (9.5)        | 2/16 (12.5)      | 0.764               | 4/28 (14.3) | 1/13 (7.7)                   |                            | 0.526   |
| Secondary, # (%) | 1/4 (25)             | 10/21 (47.6)      | 5/16 (31.3)      | 12/28 (42.9)        | 4/13 (30.8) |                                |                            |         |
| Compensated, # (%) | 2/4 (50)             | 9/21 (42.8)       | 9/16 (56.3)      | 12/28 (42.9)        | 8/13 (61.5) |                                |                            |         |
| TT (ng/ml)     | 3–9                  | 6.2 (4.8–7.5)     | 6.6 (5.2–8.5)    | 7 (5.3–9.3)         | 0.241 | 6.6 (5.2–8.4) | 6.9 (5.1–9.1) | 0.438   |
| SHBG (nmol/l)  | 10–70                | 49 (41.2–60.5)*   | 64 (43.5–92)     | 69.5 (51.8–94.5)*   | 0.034 | 59.0 (42.7–73.0) | 84.5 (56.8–113.8) | 0.010   |
| cFT (pg/ml)    | 65–260               | 98.9 (80.6–118)   | 93.6 (73.6–119.3) | 94.3 (71.9–117.8) | 0.859 | 94.9 (74.1–115.3) | 88.6 (72.0–119.0) | 0.825   |
| LH (IU/l)      | 1.5–9.0              | 3.6 (2.9–7.9)     | 6.3 (3.6–8.2)    | 6 (4–13.5)          | 0.079 | 5.2 (3.3–8.2) | 7.5 (4.1–10.7) | 0.085   |
all variables were entered, the overall model was assessed in terms of its ability to predict total hip BMD, and the relative contribution of each set of variables was also reported. In Step 1, we forced age and BMI into the analysis, to controlling for these variables. In this step, age and BMI explained 20.3% of variance associated with hip BMD. In Step 2, we entered data on HIV infection into the model as a block, with the effect of age and BMI removed, to assess whether these variables were still able to predict our dependent variable. We found that CD4 nadir count, HIV and cART duration explained an additional 10.8% of the variance. Following this procedure, Step 3 showed that TT, SHBG, cFT LH and FSH explained a further 10% of variance, controlling for previously entered variables. Finally, in Step 4, VFs alone

### Table 1 (continued)

| Total (n. 168) | Normal values (n. 21) | Normal BMD (n. 89) | Osteopenia (n. 58) | P value | No vertebral fractures (n. 126) | Vertebral fractures (n. 42) | P value |
|----------------|-----------------------|---------------------|-------------------|---------|-------------------------------|-----------------------------|---------|
| FSH (IU/l)     | 1.5–8                 | 5.2 (4.1–6.2)       | 6.9 (3.8–10.3)    | 6.8 (4.9–11.3) | 0.220 5.9 (4.1–9.5) | 6.8 (4.7–12.7)  | 0.322   |
| Calcium, serum (mg/dl) | 8.6–10.2          | 9.3 (8.8–9.7)       | 9.2 (9–9.6)       | 9.4 (9.2–9.6)  | 0.204 9.3 (9–9.7)  | 9.3 (9.1–9.5)   | 0.994   |
| Calcium, 24 h urine (mg/24 h) | 100–300           | 226.6 (163.5–314)  | 221 (156–327)    | 212.5 (122.6–297.8) | 0.570 223.3 (158.0–315.0) | 201.5 (141.5–300.5) | 0.592   |
| Phosphate, serum (mg/dl) | 2.5–4.3            | 2.4 (2.1–2.7)       | 2.6 (2.2–3)       | 2.5 (2.2–3.2)  | 0.283 2.5 (2.2–2.9) | 2.8 (2.5–3.3)  | 0.003   |
| Phosphate, 24 h urine (mg/24 h) | 400–1300          | 816.5 (732.8–1059.5) | 910.8 (715.7–1138.5) | 810 (578–1066) | 0.363 912.5 (730.1–1116.3) | 738.0 (552.5–918.0) | 0.010   |
| PTH (pg/ml)    | 11–67                 | 41.8 (32.8–76)      | 48 (32–67)        | 51 (39–63)    | 0.932 45.0 (34.0–70.0) | 50.0 (40.8–60.3) | 0.774   |
| 25-OH-vitamin D (ng/ml) | > 20              | 32 (26.2–39.5)      | 28.5 (18.9–38.5)  | 33 (19.3–42)  | 0.401 29.5 (19.2–36) | 34.5 (23.2–48.7) | 0.068   |
| Bone alkaline phosphatase (IU/l) | 10–50             | 32 (22.2–51.8)      | 34 (27–50.5)     | 39 (31–60)    | 0.357 38.0 (29.0–52.0) | 32.0 (20.0–58.0) | 0.163   |
| C-terminal telopeptide (ng/ml) | 0.1–0.7           | 0.4 (0.2–0.5)       | 0.5 (0.3–0.6)     | 0.4 (0.2–0.7) | 0.802 0.5 (0.3–0.6) | 0.3 (0.2–0.5)  | 0.266   |
| Osteocalcin (ng/ml) | < 20               | 9 (5.9–17)          | 9 (5.3–16.3)      | 11.4 (7–19.7) | 0.380 10.0 (7.0–16.5) | 9.0 (5.0–17.8) | 0.655   |
| Spine BMD (g/cm²) | 1.2 (1.1–1.2)**       | 1.0 (0.9–1.1)**     | 0.8 (0.7–0.9)**   | <0.001 1.0 (0.9–1.1) | 0.9 (0.8–1) | 0.021   |
| Spine T-score (SD) | 0.2 (0.6; 0.5)**     | −1.4 (−1.8; −1)**   | −2.9 (−3.5; −2.7)** | <0.001 −1.5 (−2.5; −0.8) | −2.3 (−3; −1.3) | 0.017   |
| Total hip BMD (g/cm²) | 1.1 (1–1.1)**        | 0.9 (0.8–1)**       | 0.8 (0.7–0.9)**   | <0.001 0.9 (0.8–1.1) | 0.8 (0.7–0.9) | 0.021   |
| Total hip T-score (SD) | 0 (−0.5; 0.4)**      | −1 (−1.5; −0.3)**   | −1.8 (−2.4; −1.2)** | <0.001 −0.9 (−1.5; −0.1) | −1.5 (−2.4; −1.1) | 0.001   |
| Femoral neck BMD (g/cm²) | 1 (0.9–1)**          | 0.8 (0.7–0.9)**     | 0.7 (0.6–0.8)**   | <0.001 0.8 (0.7–0.9) | 0.8 (0.7–0.8) | 0.091   |
| Femoral neck T-score (SD) | −0.3 (−0.8; 0)**    | −1.3 (−1.8; −1)**   | −2.1 (−2.7; −1.6)** | <0.001 −1.2 (−1.9; −0.7) | −1.8 (−2.2; −1.3) | <0.001 |
| Vertebral fractures, # (%) | 1/21 (4.8)**         | 19/89 (21.3)**      | 22/58 (37.9)**    | 0.006 /       | /                | /                |         |

Variables expressed as median (IQR) or absolute number (%) as appropriate

Comparisons for continuous variables are performed with Kruskal–Wallis, for BMD comparison, and with Mann–Whitney U test, for vertebral fractures comparison (post hoc: Bonferroni, identified in table through*). Comparison for categorial variables are performed with Pearson’s Chi Square

A p-value ≤ 0.05 is considered significant

Abbreviations: BMI body mass index, cART combined antiretroviral therapy, TT total testosterone, SHBG sex hormone-binding protein, cFT calculated free testosterone, LH luteinizing hormone, FSH follicle stimulating hormone, PTH parathyroid hormone, BMD bone mineral density
added another 4.2% of explained variance, controlling for all other factors. The final model (significant at $p = 0.008$) explained 45.3% of the variance associated with total hip BMD. Independent variables with the highest beta’s still significant in the final model for total hip BMD were BMI ($\beta = 0.37$, $p = 0.004$), TT ($\beta = 0.38$, $p = 0.032$) and FSH ($\beta = 0.34$, $p = 0.026$). With respect to femoral neck BMD, despite the final model being not significant, and therefore, not reported in Table 3, some independent variables showed significant univariate correlation (cART exposure $\beta = 0.46$, $p = 0.049$; TT $\beta = 0.49$, $p = 0.014$; SHBG $\beta = 0.42$, $p = 0.029$; cFT $\beta = 0.30$, $p = 0.038$; FSH $\beta = 0.41$, $p = 0.016$; VFs $\beta = 0.26$, $p = 0.048$).

Table 4 shows the results of a backward stepwise logistic regression carried out to assess predictive factors for VFs. Full model included as independent variables age, BMI, years of infection, cART duration, spine BMD, CD4+ nadir count, TT, SHBG, cFT, LH and FSH. At each step, non-significant variables were gradually eliminated to find the best reduced model. Final model ($p = 0.018$) included age, cART duration, TT, SHBG, cFT and FSH, and correctly classified 81.3% of cases. Older age and higher SHBG values were mild predictors of VFs (OR $= 1.04$, $p = 0.016$; OR $= 1.08$, $p = 0.025$, respectively), whereas higher TT levels were protective towards VFs (OR $= 0.41$, $p = 0.047$).

Finally, ROC curves were calculated to determine whether FSH, TT and SHBG values were predictive of osteopenia/osteoporosis (FSH), and of VFs (TT and SHBG), as shown in Fig. 2. The ROC curves of TT for VFs were not statistically significant, and therefore, not reported. On the contrary, FSH showed a low sensitivity (52.5%) but a good specificity (84.6%) in identifying osteopenic/osteoporotic patients, when threshold value was set at 6.6 IU/l (AUC = 0.645, $p = 0.039$), whereas SHBG showed a moderate sensitivity (57.1%) but a good specificity (76.2%) in identifying patients with VFs, when threshold value was set at 73 mmol/l (AUC = 0.664, $p = 0.014$).

**Discussion**

We found a high burden of bone disease in HIV-infected men under chronic cART, being over two thirds of them osteopenic/osteoporotic, and presenting with at least one VF in 25% of cases. Concurrently, we found a high prevalence of gonadal axis alterations, affecting 26.2% of patients. Importantly, we found that the impact of gonadal function on bone health is more evident on VFs than on BMD. In fact, even though some correlations between hormonal profile and BMD were found, we could not build a significant multivariate model able to predict spine BMD. Also, total hip BMD multivariate model showed only partial correlation with gonadal axis, especially with FSH, which had a negative impact. On the contrary, we found a higher prevalence of hypogonadism in patients with VFs, regardless of
gonadotropin levels. Furthermore, we found that SHBG was the main factor associated with and predictive for VFIs. On the other side, higher TT levels showed some protective role against VFIs occurrence.

With respect to BMD data, our findings for osteoporosis (34.5%) and osteopenia (53%) prevalence mainly agree with the literature, even if the prevalence of osteoporosis and osteopenia in HIV-infected men widely varies among studies ranging from 6 to 34% [1] and up to 67% [19, 20], respectively. Of note, a component of iatrogenic hypophosphatemic osteomalacia may be present in these patients, as already reported [21]. Our data on VFIs are substantial agreement with literature [22–25], and a recent metanalysis [8] showed a cumulative prevalence of morphometric VFIs of 20.2% (CI 15.7–25.6). As for hypogonadism, our findings confirm what already shown in the literature [26–31], especially when considering overt hypogonadism (12.5%).

The impact of hypogonadism on BMD in HIV-infected patients has been investigated by other studies, with partially conflicting results. Whereas some authors showed little or no correlation between BMD and testosterone levels [20, 32–34], in substantial agreement with our findings, others found an association between osteoporosis and hypogonadism [22, 35, 36]. These discrepancies probably come from different study settings, and also from different testosterone assays and cut-off used to define hypogonadism. Furthermore, as suggested by Santi et al. [20], and also supported by Shiyakova. [34], the impact of gonadal function on BMD is mainly mediated by oestradiol, which showed protective role for bone health in men with and without HIV infection. Indeed, we found that also higher levels of FSH and SHBG had a negative impact on BMD. FSH correlated with hip BMD and T-score, and FSH levels > 6.6 mUI/ml represented a good cut-off in predicting osteopenia/osteoporosis. One possible explanation is that an elevated FSH might be a more sensitive marker of testicular dysfunction than a single point testosterone [37]. Furthermore, and more importantly, although it is still a debatable issue, in the last few years accumulating evidence showed that FSH can directly impact on bone, by increasing osteoclastogenesis [38]. Hsu et al. [39] found that higher FSH levels were associated with increased bone loss at the hip over 5 years in elderly men. Moreover, Jing et al. [40] showed that FSH increase was associated with higher risk of osteoporosis/osteopenia in type 2 diabetic men. We previously showed that elevated SHBG levels are very common in HIV-infected
men [18, 41] and might represent the *primum movens* of the compensated form of hypogonadism in these patients. In fact, an increase in SHBG would lower the amount of free testosterone and oestradiol, with subsequent compensatory increase in LH production from the pituitary gland, which is able to maintain the testicular production of testosterone. Here, we found that SHBG was negatively associated with spine, hip and femoral BMD and the presence of osteopenia/osteoporosis and that it was positively associated with VFs.

Data on the impact of hypogonadism on fractures in HIV-infected men are more sparse [42], and very rarely hypogonadism was assessed. Among the few studies that evaluated the possible correlation between hypogonadism and fractures in HIV-infected patients, Borderi et al. [25] found that hypogonadism was not associated with morphometric VFs. However, they included both men and women, and did not specify how the diagnosis of hypogonadism was done. Short et al. [33] found that only the diagnosis of osteoporosis was associated with fractures in HIV-infected men, whereas other parameters, including hypogonadism, were not. However, they considered only self-reported fractures, and did not perform morphometric analysis, which may lead to underdiagnosis, being 65–75% of fragility fractures clinically *“silent”* [43]. Moreover, they used radioimmunoassay to determine free testosterone, which is unreliable [5]. Indeed, we found that normal testosterone

| Table 3 | Hierarchical multiple regression analysis on factors affecting total hip BMD |
|---------|------------------------------------------------------------------|
| Model 1 | Model 2 | Model 3 | Model 4 |
| β (st)  | Sig     | B (st)  | Sig     | B (st)  | Sig     | B (st)  | Sig     |
| Age (years) | −0.09 | 0.453 | −0.11 | 0.329 | −0.08 | 0.508 | −0.04 | 0.721 |
| BMI (kg/m²) | 0.46 | <0.001 | 0.45 | <0.001 | 0.38 | 0.003 | 0.37 | 0.004 |
| HIV infection duration (years) | −0.46 | 0.032 | −0.37 | 0.085 | −0.40 | 0.059 |
| cART duration (years) | 0.35 | 0.109 | 0.31 | 0.137 | 0.38 | 0.070 |
| CD4+ (cell/mm³) nadir | 0.23 | 0.054 | 0.20 | 0.075 | 0.20 | 0.078 |
| TT (ng/ml) | −0.34 | 0.061 | −0.38 | 0.032 |
| SHBG (nmol/l) | 0.13 | 0.439 | 0.23 | 0.186 |
| cFT (pg/ml) | 0.23 | 0.089 | 0.22 | 0.089 |
| FSH (mUI/ml) | −0.32 | 0.039 | −0.34 | 0.026 |
| LH (mUI/ml) | 0.05 | 0.765 | 0.03 | 0.831 |
| VFs | −0.23 | 0.056 |
| $R^2$ change | 0.203 | 0.108 | 0.100 | 0.042 |

Variables were entered in four different Steps (namely Model 1–4), with each independent variable being assessed for what it might add to the prediction of total hip BMD variance, after the previous variables were controlled for. The relative contribution of each set of variables is also reported ($R^2$ change). Model 1 included age and BMI as forced entries; Model 2 included HIV related data in addition; Model 3 focused on gonadal function assessment and Model 4, being the final Model, significant at $p=0.008$, included also VFs as predictor of total hip BMD. Independent variables with the highest significant beta are shown in bold.

Abbreviations: *BMI* body mass index, *cART* combined antiretroviral therapy, *TT* total testosterone, *SHBG* sex hormone-binding protein, *cFT* calculated free testosterone, *LH* luteinizing hormone, *FSH* follicle stimulating hormone, *VFs* vertebral fractures

| Table 4 | Results of backward stepwise logistic regression using prevalent VFs as dependent variable |
|---------|---------------------------------------------------------------------------------|
| B coefficient | Prevalent VFs | OR (95% CI) | Sig | Excluded variables |
| Age (years) | 0.11 | 1.12 (1.02–1.23) | 0.016 | BMI |
| cART exposure (years) | 0.09 | 1.10 (0.99–1.20) | 0.057 | HIV infection duration |
| TT (ng/ml) | −0.89 | 0.41 (0.17–0.98) | 0.047 | CD4 nadir |
| SHBG (nmol/l) | 0.08 | 1.08 (1.01–1.16) | 0.025 | Spine BMD |
| cFT (pg/ml) | 0.05 | 1.06 (0.99–1.12) | 0.077 | LH |
| FSH (mUI/ml) | −0.07 | 0.93 (0.86–1.01) | 0.079 |

Abbreviations: *BMI* body mass index, *cART* combined antiretroviral therapy, *TT* total testosterone, *SHBG* sex hormone-binding protein, *cFT* calculated free testosterone, *LH* luteinizing hormone, *FSH* follicle stimulating hormone, *VFs* vertebral fractures
levels were protective towards VFs, whereas higher SHBG values and older age were risk factors. Furthermore, we identified a possible threshold of SHBG (>73 nmol/L), over which VFs might be more often observed. The role of SHBG in predicting fractures in the general population has also been investigated in few studies. However, a recent meta-analysis by Hidayat et al. [44] showed that higher SHBG levels are associated with an increased risk of hip, vertebral and non-vertebral fractures in older adults, both men and women. In addition, high SHBG predicted incident VFs in elderly men and added information for VFs risk prediction beyond the widely used Fracture Risk Assessment Tool (FRAX) [45].

The major limitations of our study include the retrospective nature of the study and the absence of a control group of non-HIV patients. Furthermore, oestradiol, useful to better investigate gonadal function and its relationship with bone health, was not measured in many patients, and we did not collect information to clearly quantify dietary calcium and protein intake. Notwithstanding that, the strengths of our study include the detailed evaluation of hypogonadism, based on clinical evaluation and a complete hormonal assay, as suggested by most guidelines. Furthermore, we focused on the relationship between VFs and hypogonadism as a primary endpoint, a focus very rarely analysed in HIV patients, reporting novel and interesting findings.

In conclusion, we found a high burden of bone and gonadal disease in HIV-infected men under cART, and we showed that, in the multifactorial set of elements involved in the pathogenesis of bone fragility, besides low testosterone levels, FSH might have a negative impact on hip BMD, and, more importantly, higher SHBG values might be predictive for VFs occurrence in this population.

Funding Open access funding provided by Università degli Studi di Brescia within the CRUI-CARE Agreement. No funding was received to assist with the preparation of this manuscript.

Availability of data and materials Data are available upon motivate requests.

Code availability Not applicable.

Declarations

Conflicts of interest The authors have no conflicts of interest to declare that are relevant to the content of this article.

Research involving human participants and/or animals Ethic Committee of Brescia Province (Comitato Etico di Brescia—August 2020 NP 3898).

Informed consent Informed consent was obtained from all individual participants included in the study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Maffezzoni F, Porcelli T, Delbarba A, Pezzaioni LC, Properzi M, Cappelli C, Castelli F, Quirros-Roldan ME, Ferlin A (2020) Hypogonadism and bone health in men with HIV. Lancet HIV 7:e782–e790
2. Babu H, Ambikan AT, Gabriel EE et al (2019) Systemic inflammation and the increased risk of inflamm-aging and age-associated diseases in people living with HIV on long term suppressive antiretroviral therapy. Front Immunol 10:1965
3. Birabaharan M, Kaelber DC, Karris MY (2021) Bone mineral density screening among people with HIV: a population-based analysis in the United States. Open Forum Infect Dis 8:ofab081
4. Corona G, Goulis DG, Huhtaniemi I, Zitzmann M, Toppari J, Forti G, Vanderschueren D, Wu FC (2020) European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: Endorsing organization: European Society of Endocrinology. Andrology. https://doi.org/10.1111/andr.12770
5. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA (2018) Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 103:1715–1744
6. Goh SSL, Lai PSM, Tan ATB, Ponnampalavanar S (2018) Reduced bone mineral density in human immunodeficiency
virus-infected individuals: a meta-analysis of its prevalence and risk factors: supplementary presentation. Osteoporos Int 29:1683
7. Chang CJ, Chan YL, Pramukti I, Ko NY, Tai TW (2021) People with HIV infection had lower bone mineral density and increased fracture risk: a meta-analysis. Arch Osteoporos 16:47
8. Ilha TASH, Comim FV, Copes RM, Compton JE, Premaor MO (2018) HIV and vertebral fractures: a systematic review and meta-analysis. Sci Rep 8:7838
9. Casado JL, Bañón S, Andrés R, Perez-Elías MJ, Moreno A, Moreno S (2014) Prevalence of causes of secondary osteoporosis and contribution to lower bone mineral density in HIV-infected patients. Osteoporos Int 25:1071–1079
10. Walker Harris V, Brown TT (2012) Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies. J Infect Dis 205(Suppl 3):S391–398
11. De Toni L, Agoulnik AI, Sandri M, Foresta C, Ferlin A (2019) INSL3 in the musculo-skeletal system. Mol Cell Endocrinol 487:12–17
12. Ferlin A, Selice R, Carraro U, Foresta C (2013) Testicular function and bone metabolism—beyond testosterone. Nat Rev Endocrinol 9:546–554
13. Almeida M, Laurent MR, Dubois V, Claessens F, O’Brien CA, Bouillon R, Vanderschueren D, Manolagas SC (2017) Estrogens and androgens in skeletal physiology and pathophysiology. Physiol Rev 97:135–187
14. Porcelli T, Maffezzoni F, Pezzaioli LC, Delbarba A, Cappelli C, Ferlin A (2020) Management of endocrine disease: Male osteoporosis—diagnosis and management—should the treatment and the target be the same as for female osteoporosis? Eur J Endocrinol 183:R75–R93
15. Pedrazzoni M, Girasole G, Bertoldo F et al (2003) Definition of a population-specific DXA reference standard in Italian women: the Densiometric Italian Normative Study (DINS). Osteoporos Int 14:978–982
16. Camacho PM, Petak SM, Binkley N et al (2020) American association of clinical endocrinologists/american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 26:3–46
17. Genant HK, Jergas M (2003) Assessment of prevalent and incident vertebral fractures in osteoporosis research. Osteoporos Int 14(Suppl 3):S43–55
18. Pezzaioli LC, Quiros-Roldan E, Paghera S, Porcelli T, Maffezzoni F, Delbarba A, Cappelli C, Castelli F, Ferlin A (2021) The importance of SHBG and calculated free testosterone for the diagnosis of symptomatic hypogonadism in HIV-infected men: a single-centre real-life experience. Infection 49:295–303
19. Kruger MJ, Nell TA (2017) Bone mineral density in people living with HIV: a narrative review of the literature. AIDS Res Ther 14:35
20. Santi D, Mdeo B, Carli F, Zona S, Brigante G, Vescini F, Guaraldi G, Rochira V (2016) High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine 41:512–517
21. Borderi M, Calza L, Colangeli V, Vanino E, Viale P, Gibellini D, Re MC (2014) Prevalence of sub-clinical vertebral fractures in HIV-infected patients. New Microbiol 37:25–32
22. Pepe J, Isidori AM, Falciano M et al (2014) Effect of risedronate in HIV-infected patient. Clin Rheumatol 33:298–308
23. Jing Y, Wang X, Yu J, Zhou Y, Tao B, Sun L, Liu J, Zhao H (2020) Follicle-stimulating hormone (FSH) Action on Spermatogenesis: A Focus on Physiological and Therapeutic Roles. J Clin Med. https://doi.org/10.3390/jcm9041104
24. Torti C, Mazzetti G, Soldini PA, Focè E, Maroldi R, Gotti D, Carosi G, Giustina A (2012) High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine 41:512–517
25. Borderi M, Calza L, Colangeli V, Vanino E, Viale P, Gibellini D, Re MC (2014) Prevalence of sub-clinical vertebral fractures in HIV-infected patients. New Microbiol 37:25–32
26. Gomes AR, Souto Pereira, Silva PG, Sousa-Pinto B, Almeida F, Sarto A, Carvalho D, Freitas P (2016) Prevalence of testosterone deficiency in HIV-infected men under antiretroviral therapy. BMC Infect Dis 16:628
27. Monroe AK, Dobs AS, Palella FJ, Kingsley LA, Witt MD, Brown TT (2014) Morning free and total testosterone in HIV-infected men: implications for the assessment of hypogonadism. AIDS Res Ther 11:6
28. Sunchatawirul K, Tantiwongse K, Chatassong P, Thongyen S, Chumpathan A, Manosuthi W (2012) Hypogonadism among HIV-infected men in Thailand. Int J STD AIDS 23:876–881
29. Rochira V, Zirilli L, Orlando G, Santi D, Brigante G, Diazz C, Carli F, Carani C, Guaraldi G (2011) Premature decline of serum total testosterone in HIV-infected men in the HAART-era. PLoS ONE 6:28512
30. Rietshel P, Corcoran C, Stanley T, Basgnozzi A, Grainpoon S (2000) Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy. Clin Infect Dis 31:1240–1244
31. Rochira V, Diazz C, Santi D, Brigante G, Ansaloni A, Decaroli MC, De Vincentis S, Stentarelli C, Zona S, Guarald G (2015) Low testosterone is associated with poor health status in men with human immunodeficiency virus infection: a retrospective study. Andrology 3:298–308
32. Gijsen ML, Vrouwenraets SM, Steinrover R, Lip P, Reiss P, Wit FW, Prins JM (2010) High prevalence of reduced bone mineral density in primary HIV-1-infected men. AIDS 24:2233–2238
33. Short CE, Shaw SG, Fisher MJ, Walker-Bone K, Gilleece YC (2014) Prevalence of and risk factors for osteoporosis and fracture among a male HIV-infected population in the UK. Int J STD AIDS 25:113–121
34. Shaiyкова A, Pasquet A, Goujard C et al (2018) Reduced bone mineral density among HIV-infected, virologically controlled young men: prevalence and associated factors. AIDS 32:2698–2706
35. Pepe J, Isidori AM, Falciano M et al (2014) Effect of risedronate in osteoporotic HIV-males, according to gonadal status: a pilot study. Endocrine 47:456–462
36. Teichmann J, Lange U, Discher T, Lohmeyer J, Stracke H, Bretzel RG (2009) Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active antiretroviral-therapy (HAART). Eur J Med Res 14:59–64
37. Santi D, Crépieux P, Reiter E, Spaggiari G, Brigante G, Casarini L, Rochira V, Simoni M (2020) Follicle-stimulating Hormone (FSH) and Estradiol in HIV-Infected Males in Italy: A Cross-sectional Study. Front Endocrinol (Lausanne) 10:136
38. Lizzneva D, Rahimova A, Kim SM et al (2019) FSH beyond fertility. Front Endocrinol (Lausanne) 10:136
39. Hsu B, Cumming RG, Seibel MJ, Naganathan V, Blyth FM, Bleicher K, Dave A, Le Couteur DG, Waite LM, Handelsman DJ (2015) Reproductive hormones and longitudinal change in bone mineral density and incident fracture risk in older men: the concord health ageing in men project. J Bone Miner Res 30:1701–1708
40. Jing Y, Wang X, Yu J, Zhou Y, Tao B, Sun L, Liu J, Zhao H (2020) Follicle-stimulating hormone and estradiol are associated with bone mineral density and risk of fractures in men with type 2 diabetes mellitus. J Diabetes 12:426–437
41. Quiros-Roldan E, Porcelli T, Pezzaioli LC, DeGlioni M, Paghera S, Properzi M, Focè A, Carriero C, Castelli F, Ferlin A (2021)
Hypogonadism and liver fibrosis in HIV-infected patients. J Endocrinol Invest. https://doi.org/10.1007/s40618-021-01512-9

42. Pramukti I, Lindayani L, Chen YC, Yeh CY, Tai TW, Fetzer S, Ko NY (2020) Bone fracture among people living with HIV: A systematic review and meta-regression of prevalence, incidence, and risk factors. PLoS ONE 15:e0233501

43. Lems WF, Paccou J, Zhang J et al (2021) Vertebral fracture: epidemiology, impact and use of DXA vertebral fracture assessment in fracture liaison services. Osteoporos Int 32:399–411

44. Hidayat K, Du X, Shi BM (2018) Sex hormone-binding globulin and risk of fracture in older adults: systematic review and meta-analysis of observational studies. Osteoporos Int 29:2171–2180

45. Vandenput L, Mellström D, Kindmark A et al (2016) High serum SHBG predicts incident vertebral fractures in elderly men. J Bone Miner Res 31:683–689

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.